Home Cart Sign in  
Chemical Structure| 898280-07-4 Chemical Structure| 898280-07-4

Structure of XL228
CAS No.: 898280-07-4

Chemical Structure| 898280-07-4

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

XL228 is a protein kinase inhibitor targeting IGF1R, the Aurora kinases, FGFR1-3, ABL and SRC family kinases.

Synonyms: XL228

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of XL228

CAS No. :898280-07-4
Formula : C22H31N9O
M.W : 437.54
SMILES Code : CN1CCN(C2=CC(NC3=NNC(C4CC4)=C3)=NC(NCC5=CC(C(C)C)=NO5)=N2)CC1
Synonyms :
XL228
MDL No. :MFCD26793867

Safety of XL228

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H315-H319-H302
Precautionary Statements:P501-P270-P264-P280-P302+P352-P337+P313-P305+P351+P338-P362+P364-P332+P313-P301+P312+P330

Related Pathways of XL228

epigenetics
DNA
RTK

Isoform Comparison

Biological Activity

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT00526838 Cancer|Lymphoma PHASE1 TERMINATED 2025-12-10 UCLA Jonsson Comprehensive Can... More >>cer Center, Los Angeles, California, 90095, United States|Winship Cancer Institute of Emory University, Atlanta, Georgia, 30322, United States|University of Michigan Health System, Ann Arbor, Michigan, 48109, United States|Duke University Medical Center, Durham, North Carolina, 27710, United States Less <<
NCT00464113 Chronic Myeloid Leukemia|Leuke... More >>mia, Lymphoblastic, Acute, Philadelphia-Positive Less << PHASE1 TERMINATED 2025-04-11 UCLA School of Medicine, Los A... More >>ngeles, California, 90095-1678, United States|University of California San Francisco, San Francisco, California, 94143-1270, United States|Georgetown University Medical Center, Lombardi Comprehensive Cancer Center, Washington, District of Columbia, 20007, United States|H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida, 33612, United States|University of Michigan Health System, Ann Arbor, Michigan, 48109, United States|MD Anderson Cancer Center, Houston, Texas, 77030, United States Less <<

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.29mL

0.46mL

0.23mL

11.43mL

2.29mL

1.14mL

22.86mL

4.57mL

2.29mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories